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A B S T R A C T
Latent tuberculosis infection (LTBI) is established in over 90% of persons infected with Mycobacterium
tuberculosis (Mtb), from whom new active TB cases will arise. Understanding the spatio-temporal
dynamics of host immune responses in LTBI granulomas is essential to designing effective post-exposure
therapies that inhibit progression to TB. Information arising from cancer studies and other modalities –
where local chronic inﬂammation leads to immunopathology – can help provide insights into the
biological pathways at play in LTBI granulomas. Translational studies using patient material as well as
LTBI+ donor-derived tissue samples are instrumental in understanding the various components of
granuloma dynamics, immunological landscapes therein and how this could help to identify therapeutic
targets. Deep sequencing technologies may aid to decipher the genetic changes in lung granuloma and
blood samples from LTBI+ individuals associated with progression to active TB disease. This may lead to
advancement of development of targeted Host-Directed Therapies (HDTs) and their evaluation as adjunct
TB therapies for improving treatment outcomes for LTBI and pulmonary TB.
© 2019 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Tuberculosis (TB) has plagued humankind for centuries and has
caused over one billion deaths. Today, an estimated 2 billion people
worldwide have latent TB infection (LTBI). Humans are the
main reservoir of Mycobacterium tuberculosis (Mtb) and human
to human spread primarily occurs through inhalation of respira-
tory aerosols and secretions containing Mtb exhaled from a patient
with active pulmonary TB. Despite intense study over the past six
decades the sequence of human host-Mtb interactions and* Corresponding author at: Champalimaud Centre for the Unknown, Avenida
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tion, remain a mystery (Zumla et al., 2011). The granuloma was
thought to be a result of protective cell-mediated and has
been central to the study of pathogenesis of TB and other
intracellular pathogens (James and Zumla, 1999). A spectrum of
granulomatous changes has been described from complete
resolution, to continuing granuloma turnover with protective
and deleterious inﬂammation, caseous necrosis, ﬁbrosis and
scarring of tissue leading to long-term functional disability (Drain
et al., 2018). Technological advances over the years have enabled
more detailed studies at molecular and cellular level, several
recent publications have questioned whether the granuloma or
its individual immune components make the granuloma a ‘friend’
or a ‘foe’ (Rubin, 2009; Galizia and Marti, 2018). Thus, gaining a
deeper understanding of the host-pathogen interactions in
persons harbouring LTBI may hold quintessential clues to
achieving the WHO’s goal of eliminating TB as a public health
threat by 2050.ious Diseases. This is an open access article under the CC BY-NC-ND license (http://
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individual lesions in the same patient evolve over time, just as how
cancer lesions do. This evolutionary process is mediated and
inﬂuenced by exposure to drugs, the hosts genetics as well as that
of the infecting Mtb species (Ankrah et al., 2016). Studies show that
position emission tomography (PET) with [18F]ﬂuoro-2-deoxy-D-
glucose (FDG) is able to monitor lesions in patients with subclinical
TB – which could have arisen from a previously LTBI state – and the
behavioural pattern of individual lesions which are likely to
perpetrate the development of symptomatic clinical disease (Drain
et al., 2018). Since most people infected with Mtb do not develop
active clinical disease, LTBI presents a unique and challenging
opportunity to understand the intricate relationship between host
cells in the granuloma, the contribution of the stromal compart-
ment to sustain infection and how the local immune responses is
placed therein. Thorough dissection of these biological component
which collectively govern host-pathogen interactions and patho-
genesis will reveal essential information necessary for developing
next-generation drugs and therapies.
Genetic aberrations in the Mtb genome usually make the bacilli
refractory to antibiotics and resistant to immune attack. However,
we have yet to uncover whether some of these mutations aid their
long survival in the LTBI granuloma without attracting much
attention from immune cells. Furthermore, an individual’s human
leukocyte antigen (HLA) background, naturally occurring varia-
tions in immune-related genes and selective pressure affecting
gene expression patterns may inﬂuence local host-pathogen
interactions in the LTBI granuloma and later, the development of
clinical TB. Indeed, the genetic basis of susceptibility to TB is being
roped back into the limelight due to vaccine efﬁcacy studies and
evaluation of new biomarkers for host-directed therapy (HDT) as
well as to predict clinical responses to standard anti-TB treatment
(Goletti et al., 2018).
Emerging data from clinical studies provide staunch ground for
accounting for immune-cell types as well as surface or effector
molecule expression proﬁles to better gauge the pathophysiologi-
cal status linking LTBI and clinical TB. Natural killer (NK) cells,
previously underemphasised in protection to TB, are now
acknowledged as important modulators of progression to active
TB from LTBI (Roy Chowdhury et al., 2018). An increase of CD4+ and
CD8+ mucosal-associated invariant T cells (MAIT) in peripheral
blood of individuals harbouring LTBI compared to uninfected
control subjects has also been reported (Paquin-Proulx et al., 2018).
The existence of a clonotypic T-cell receptor (TCR) repertoire in the
LTBI is associated with protection against clinical disease (Tully
et al., 2005), which requires more detailed analysis in light of
recent ﬁndings examining TCR diversity in patients with TB. More
recent work has re-examined the structural diversity of the TCR
repertoire in blood from patients with TB where – in comparison to
age- and exposure-matched controls – a restricted TCR-repertoire
exists and a broader TCR repertoire was associated with better
clinical performance among patients (Luo et al., 2012). In addition,
LTBI+ individuals exhibited a preferred usage of certain TCR
clonotypes, which was further analysed in a different study where
the TCR complementarity-determining region 3 (CDR3), which is
responsible for antigen speciﬁcity, was shared among individuals
in association with HLA restriction (Glanville et al., 2017). This
helps elucidating the structural anatomy of the T-cell response in
LTBI+ individuals, warrants a more detailed description of TB
granulomas at different stages.
Differences in the TCR repertoire may be governed by the sub-
anatomy of the TB granuloma as well as infection with different
Mtb species or re-infection – which occurs more frequently than
previously thought (Cohen et al., 2012). The notion that seeding of
commonly shared TCR clonotypes in lung tissue occurs early in
embryonal development suggests that a pre-wired TCR repertoireand dual recognition patterns with shared TCRs recognising
evolutionarily preserved relevant target structures (Pogorelyy
et al., 2017) exists from early life while demanding further
investigation. The comparison of T-cell clones from twins, humans
of different ages and cord blood showed that prenatally-formed T-
cell clones persist in the mature organism for decades, providing a
‘pre-programmed’ immune-receptor repertoire (Pogorelyy et al.,
2017). This suggests that the TCR repertoire recognising potential
antigenic targets, such as tumour antigens, or pathogens, has been
shaped earlier in life. The consequences of prenatal infections or
exposure to other target antigens and productive anti-tumour
immune responses is now a ﬁeld of active investigation.
Comparative studies of TCR repertoires from the TB granuloma
with that from blood in conjunction with HLA allelic selection and
expression proﬁles across patient cohorts in different geographical
locations will yield valuable clinical data for mapping key host
response patterns and characteristics.
The anatomy in granuloma lesions and lessons from tumour
heterogeneity
A fresh look into the functional diversity and anatomy in TB
granulomas can be inspired by cancer studies, comprising different
subgroups based on immune-reactivity patterns that may also be
linked to sub-anatomical areas within the lesion (Gerlinger et al.,
2012; Thorsson et al., 2018). The local anti-tumour immune
response landscape supports the notion that the spatial relation-
ship of inﬂammatory cells is vital in conferring in-situ protective
immune responses (Thorsson et al., 2018). Adaptive cellular
immune responses herein may receive ‘bystander’ activation
signals via alternate ligands, molecular mimicry or even ‘in-built’
cross-reactivity (Whiteside et al., 2018), as recently described for
TCR gamma-delta (gd) exhibiting exquisite antigen speciﬁcity as
well as a broad recognition of stress signals via TCR germline-
encoded motifs (Melandri et al., 2018). Endogenously-produced
cytokines such as IL-15 and IL-7 expressed in TB granulomas
(Maeurer et al., 1999) can stimulate memory CD8+ T cells and
induce an effect comparable to speciﬁc TCR ligation, with
subsequent production of IFN-g, perforin and granzyme B (Liu
et al., 2002). Thus, the interplay between various immune-cell
subsets in the disease microenvironment i.e. interaction of CD8+ T
cells and other immune cells, e.g. CD4+, NK cells, Tregs, macro-
phages and myeloid-derived suppressor cells (Liu et al., 2002) is
critical for protective cellular immune responses. Furthermore,
spatial proximity of T cells to cancer cells has been strongly
associated with increased survival in patients with cancer
(Carstens et al., 2017). Similar studies examining the 3D interaction
of T cells in TB granulomas with other immune cell subsets,
including Mtb-infected cells and epithelial cells – given the
similarities between TB granulomas and cancerous lesions –
warrant deeper insights.
Each TB granuloma appears to be ‘unique’ concerning the
overall cytokine production pattern as well as the different areas
within the same lesion, representing a challenge to applying
immuno-modulatory HDTs (Ndlovu and Marakalala, 2016). Some
TB granulomas may contain dysfunctional T cells associated with
chronic antigen exposure and immune exhaustion akin to
subpopulations of tumour-inﬁltrating T lymphocytes (TIL) in
cancer (Anderson et al., 2017). The heterogeneity in TB granulo-
mas may also be associated with a simple sample bias of the
granuloma tissue area examined, such as described for tumour
heterogeneity (Gerlinger et al., 2012; Thorsson et al., 2018). T-cell
populations which are already resident in the lung are also of
great importance in orchestrating host responses in the LTBI
granuloma based on information from other modalities, as
described in Table 1.
Table 1
Features of tissue-resident memory (TRM) T cells which may be pertinent to LTBI.
Main characteristics of TRM T cells Strongly CD103+ CD69+; some exist in CD103- CD69- compartments
Comprise 40% of lung T-cell pool; not found in blood (among PBMCs)
Produce more perforin and less granzyme B
May clear dormant Mtb reservoirs if activated/mobilised
TRM T-cell antigen speciﬁcity and
priming
Local antigen exposure drives TCR diversity of TRM T cells
Genetic make-up of individuals plays a bid role i.e. mutational load, pathogen invasion, HLA background
Some HLA elements may protect against infection but induce autoimmunity i.e. HLA-B57 is a ‘good antigen presenter’ for
inﬂuenza-speciﬁc epitope recognition yet it is also associated with drug-induced autoimmunity
Certain HLA restriction elements may be associated with superior Mtb clearance, thus enabling sterilising immunity in some
people – in-depth genetic analysis of clinical samples required
Effect of tissue microenvironment on TRM
T-cell biology
Molecular studies have identiﬁed 6 distinct immune proﬁles in cancer lesions: wound healing, IFN-g-dominant,
inﬂammatory, lymphocyte depleted, immunologically ‘silent’ and TGF-β-dominant
These phenotype-genotype combinations dictate the nature and biology of inﬁltrating as well as resident immune cells,
response to immunotherapy as well as chemotherapy and survival
Infecting pathogens also dictate the local immunological signature i.e. EBV is linked to lower B cells and HBV associates with
high TCR gd numbers and IL-17 expression
Exaggerated pro-inﬂammatory cytokine production i.e. TNF-α, IL-6, IFN-g, IL-18, type 1 interferons and vascular endothelial
growth factor (VEGF) induces aberrant neovascularisation and affect immune-cell trafﬁcking and movement within the tissue
microenvironment – also shown in TB granulomas
The number of PD-1+ tissue-inﬁltrating and TRM cells – particularly antigen-experienced CD8+ T cells – affects targeted
immune responses to cancer and infected host cells alike
IL-13, IL-4, IL-5 and TGF-β activate regulatory T-cell subsets, which dampen antigen-speciﬁc lymphocyte responses
An intricate control of inﬂammatory responses by TRM subsets in LTBI lesions are likely to dictate whether active disease
would ensure. TGF-β upregulation, for instance, is a known characteristic of patients with active TB
Memory phenotypes of TRM T cells Effector memory cells (CD45- CCR7-) likely to be excellent at mediating disease regression in patients, based on adoptive cell
therapy (ACT) studies in cancer
Terminally-differentiated precursor-like T cells (CCR7+, CD45RA+) have reduced telomerase activity, shorter telomeres and
lack tissue homing capacity i.e. tissue homing chemokine receptor CXCR3 expression
CXCR3+ T cells in SCC tissue correlated positively with increased patient survival – also in the presence of pulmonary TB
lesions
Other TRM T-cell subsets Double-negative (DN) T cells may arise from CD4+ or CD8+ T cells
May also exhibit a stem cell-like (CD103+, CD95+, CD117+) immunophenotype, consistent with favourable outcomes in cancer
and TB
TCR gd T cells, MAIT cells, invariant NK T cells
There is already some evidence of these unconventional T cells playing a role in TB immunopathology as well as protection i.e.
Vg9Vd2 T cells and MR1-restricted MAIT as well as iNKT cells in LTBI. Their role early after infection and during LTBI
establishment in humans warrants further elucidation
S60 M. Rao et al. / International Journal of Infectious Diseases 80 (2019) S58–S61Changes in the gut and lung microbiomes and how this may
inﬂuence establishment of LTBI, local granuloma-associated
immune responses and or progression to active TB disease is
worth investigating. The gut-lung axis is of particularly importance
in augmenting immune responses originating in the gut and
exerting effects in the thoracic region (Bacher et al., 2019).
Integrating the gut and lung microbiome proﬁle for predicting
progressors from LTBI and patients with active TB who are likely to
respond to therapy must be considered in future clinical studies.
Conclusion
Dissecting the heterogeneity and dynamics of LTBI granulomas
will yield a plethora of information regarding important aspects of
biology: immune responses, mutational burden induced by Mtb
infection and an individual’s microbiome proﬁle. Cutting-edge
technology such as deep sequencing and multiplatform immuno-
logical analysis will help develop a wholistic framework to better
understand TB pathogenesis and the tenets of host protective
mechanisms, which will collectively aid the development of
effective HDTs.
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